Clinical Trials Logo
  1. Home
  2. Neurocognitive Impairment
  3. NCT04242004

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Neurocognitive Impairment Clinical Trial

Official title:
Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients: A Randomized, Double-blind, Placebo-controlled Study

Clinical Trial Summary

Neurocognitive impairment (NCI) is one of the serious complications of elderly HIV-infected patients. The destruction of intestinal mucosal barrier and imbalance of bacterial flora caused by aging and HIV infection may be an important factor promoting the occurrence of NCI. Therefore, it is important to understand changes in gut microbiota of HIV-infected patients with NCI. Higher dietary intake of the essential fatty acid docosahexaenoic (DHA) has been associated with better cognitive performance in several epidemiological studies. To date, data are limited showing that DHA administration leads to benefits for behavioral disorders by modulating gut microbiota composition; the few studies on this subject, mostly completed in animal models. Moreover，low levels of DHA have been found in HIV-infected patients. The effect of DHA supplementation on gut microbiota and NCI status of HIV-positive patients have not been evaluated yet. Investigators aim to implement a case-control study to identify the relationship between gut microbiota and NCI in HIV-infected patients. At the meantime, investigators aim to implement a randomized, double-blind, placebo-controlled clinical trial to assess DHA supplementation in HIV-infected patients with NCI for 16 weeks. The effect of DHA on gut microbiota and NCI were evaluated. Also, investigators aim to identify if the benefits for NCI of DHA caused by modulating gut microbiota composition and metabolites.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04242004
Study type Interventional
Source Fudan University
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date October 30, 2019
Completion date May 1, 2020
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01692236 - Brain Imaging for HIV-Associated Thinking and Mood Disorders
Completed NCT00533884 - Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic N/A
Completed NCT01553097 - Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty N/A
Completed NCT01014195 - Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors N/A
Recruiting NCT04317742 - eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer N/A
Completed NCT02835820 - Effects of Diet on Brain Processing N/A